Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.

about

Adherence to therapies in cystic fibrosis: a targeted literature review.Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations.

P2860

Q39096768-83B1EACE-9F40-46C5-9C31-6C1012D692CE Q55517629-2A8D91B9-799C-4819-912F-183AA18E8EC6

P2860

Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.

Item

http://www.wikidata.org/entity/Q39853898

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Healthcare resource utilizatio ...... patients with cystic fibrosis.

@en

Healthcare resource utilizatio ...... patients with cystic fibrosis.

@nl

type

Item

label

Healthcare resource utilizatio ...... patients with cystic fibrosis.

@en

Healthcare resource utilizatio ...... patients with cystic fibrosis.

@nl

prefLabel

Healthcare resource utilizatio ...... patients with cystic fibrosis.

@en

Healthcare resource utilizatio ...... patients with cystic fibrosis.

@nl

P1476

Healthcare resource utilizatio ...... patients with cystic fibrosis.

@en

P2093

Brendan Limone

http://www.w3.org/2001/XMLSchema#string

Ellison D Suthoff

http://www.w3.org/2001/XMLSchema#string

Gregory S Sawicki

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Wagener

http://www.w3.org/2001/XMLSchema#string

Lasair O'Callaghan

http://www.w3.org/2001/XMLSchema#string

Mac Bonafede

http://www.w3.org/2001/XMLSchema#string

P2860

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis

The impact of medication adherence on lung health outcomes in cystic fibrosis.

Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial.

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

Determinants of adherence in adults with cystic fibrosis.

Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

Barriers to adherence in adolescents and young adults with cystic fibrosis: a questionnaire study in young patients and their parents

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

P304

845-851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/13696998.2016.1178125

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27074519

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.

about

P2860

P2860

Healthcare resource utilization associated with ivacaftor use in patients with cystic fibrosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921